Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive remote ischaemic postconditioning and hypothermia therapy in acute encephalopathy with biphasic seizures.

Pediatric research·2026
Same author

Markedly elevated bone mineral density in genetically elusive familial hypocalciuric hypercalcemia: A case report with targeted genetic analysis of eight candidate genes.

Bone reports·2026
Same author

Utility of the Rett syndrome behavior questionnaire (RSBQ) for Japanese patients with Rett syndrome: A pilot study.

Brain & development·2026
Same author

Response to: "The Loss and Dysfunction of Smooth Muscle Cells in MELAS Are Not the Only Cause for Gastrointestinal Dysmotility".

Neurogastroenterology and motility·2026
Same author

Growth hormone therapy in a patient with short stature due to fetal alcohol syndrome: seven-year follow-up.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology·2026
Same author

Loss of Myofilaments in Gastrointestinal Smooth Muscle: A Novel Pathological Finding in MELAS-Associated Chronic Intestinal Pseudo-Obstruction.

Neurogastroenterology and motility·2026

Related Experiment Video

Updated: Jul 17, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

MELAS and L-arginine therapy.

Yasutoshi Koga1, Yukihiro Akita, Junko Nishioka

  • 1Department of Pediatrics and Child Health, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830-0011, Japan. yasukoga@med.kurume-u.ac.jp

Mitochondrion
|February 6, 2007
PubMed
Summary

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) patients have lower L-arginine levels. Supplementation with L-arginine improved endothelial function and reduced stroke-like episodes in MELAS.

More Related Videos

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

Related Experiment Videos

Last Updated: Jul 17, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

Area of Science:

  • Neurology
  • Biochemistry
  • Vascular Biology

Background:

  • Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a mitochondrial disorder.
  • Endothelial dysfunction is implicated in the pathophysiology of MELAS.
  • L-arginine is a crucial substrate for nitric oxide synthesis, vital for endothelial function.

Purpose of the Study:

  • To investigate endothelial function in MELAS patients.
  • To evaluate the therapeutic effects of L-arginine supplementation in MELAS.

Main Methods:

  • Assessed L-arginine concentrations in MELAS patients during acute phases.
  • Measured flow-mediated dilation (FMD) to evaluate endothelial function.
  • Administered L-arginine via infusion and oral supplementation.

Main Results:

  • MELAS patients exhibited significantly lower L-arginine levels compared to controls.
  • L-arginine infusions rapidly improved stroke-like symptoms.
  • Two years of oral L-arginine supplementation normalized endothelial function and plasma L-arginine levels.
  • Oral L-arginine significantly decreased the frequency and severity of stroke-like episodes.

Conclusions:

  • L-arginine deficiency is present in MELAS.
  • L-arginine supplementation demonstrates therapeutic potential for managing stroke-like episodes and improving endothelial function in MELAS.
  • L-arginine therapy offers a promising approach for MELAS treatment.